Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 11, 2006, Pages 1337-1345

  Perk, Lars R ^a   Visser, Otto J ^a   Stigter Van Walsum, M ^a   Vosjan, Maria J W D ^a   Visser, Gerard W M ^a   Zijlstra, Josée M ^a   Huijgens, Peter C ^a   Van Dongen, Guus A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Ibritumomab tiuxetan; Immuno PET; Radioimmunotherapy; Yttrium 90; Zirconium 89

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IBRITUMOMAB TIUXETAN; IBRITUMOMAB TIUXETAN ZR 89; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; YTTRIUM 90; ZIRCONIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG MONITORING; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; IMMUNOREACTIVITY; ISOTOPE LABELING; MOUSE; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY; RADIOIMMUNOTHERAPY; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; ORGAN SPECIFICITY; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TISSUE DISTRIBUTION; WHOLE-BODY COUNTING; YTTRIUM RADIOISOTOPES; ZIRCONIUM;

EID: 33750305681     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0160-0     Document Type: Article

References (18)

1. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-2463
2. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262-3269
3. 90Y-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann Oncol 2005;16:786-792
4. Winter JN. Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma. Clin Lymphoma 2004;5 Suppl 1:22-26
5. Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005;106:2896-2902
6. Verel I, Visser GWM, van Dongen GAMS. The promise of immuno-PET in radioimmunotherapy. J Nucl Med 2005;46 Suppl 1:164-171
7. 90Y-labeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:92-98
8. 111In radiolabels. J Nucl Med 2001;42:1281-1287
9. Verel I, Visser GWM, Boellaard R, Stigter-Van Walsum M, Snow GB, Van Dongen GAMS. Zr-89 immuno-PET: comprehensive procedures for the production of Zr-89-labeled monoclonal antibodies. J Nucl Med 2003;44:1271-1281
10. Verel I, Visser GWM, Boellaard R, Boerman OC, Van Eerd J, Snow GB, et al. Quantitative Zr-89 immuno-PET for in vivo scouting of Y-90-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med 2003;44:1663-1670
11. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the immunoreactive fraction of radiolabeled monoclonal-antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72:77-89
12. 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2003;123:454-462
13. 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005;46:1898-1906
14. Verel I, Visser GWM, Boerman OC, Van Eerd JEM, Finn R, Boellaard R, et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm 2003;18:655-661
15. van Gog FB, Visser GWM, Klok R, van der Schors R, Snow GB, van Dongen GAMS. Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics. J Nucl Med 1996;37:352-362
16. van Gog FB, Visser GWM, Stroomer JWG, Roos JC, Snow GB, van Dongen GAMS. High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions. Cancer 1997;80:2360-2370
17. 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol 1999;15:1017-1025
18. Camera L, Kinuya S, Garmestani K, Brechbiel MW, Wu C, Pai LH, et al. Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA). Eur J Nucl Med 1994;21:640-646